Canaccord lowered the firm’s price target on Stoke Therapeutics to $20 from $21 and keeps a Buy rating on the shares. The firm believes there is more room for upside especially if STOK reaches regulatory alignment on a Phase 3 design for STK-001 for Dravet Syndome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Therapeutics reports Q1 EPS (57c), consensus (61c)
- Stoke Therapeutics CFO Stephen Tulipano to resign, Thomas Leggett to succeed
- Stoke Therapeutics appoints Jason Hoitt as Chief Commercial Officer
- Stoke Stock (NASDAQ:STOK) Gains on Drug Update; Is There More Upside Left?
- Stoke Therapeutics Launches Public Offering for Clinical Development